SREERAM GONNALAGADDA: Open Payments
NPI 1568520187 · FRISCO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,012 in 32 payments from 13 companies in 2025. Trend: 2023 $571 · 2024 $369 · 2025 $1,012
Food & beverage: $1,012
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 4 | $313 |
| Kowa Pharmaceuticals America, Inc. | 6 | $206 |
| Amgen Inc. | 2 | $138 |
| AstraZeneca Pharmaceuticals LP | 6 | $93 |
| Abbott Laboratories | 4 | $79 |
| PFIZER INC. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Exact Sciences Corporation | 1 | $19 |
Products named: DEXCOM G7 GSS (161), ZORYVE, Otezla, FREESTYLE LIBRE 3, XELJANZ, BREZTRI, CAPLYTA, FARXIGA.
Industry payments across TX — which companies pay providers there.
